Summary.-The prevalence of high levels of circulating ACTH-like immunoactivity was determined in 134 patients with lung cancer, using reference ranges from 52 age-and sex-matched patients with non-malignant lung disease. Two studies used ACTH radioimmunoassays with different specificities. Study A used an unextracted plasma or serum assay for total ACTH immunoactivity. High serum ACTH levels occurred in 24% of patients with small-cell carcinoma and 3O% of patients with nonsmall-cell cancer. In patients with small-cell carcinoma, levels were high in 120,, with limited disease and 32% with extensive disease.
Study B used an ACTH assay after plasma extraction by porous glass, which measured mainly regular 1-39 ACTH. Here no lung-cancer patient had levels above the reference range, suggesting that the high levels in Study A may be due to plasma ACTH components which are poorly extracted by porous glass.
It is concluded that high circulating ACTH immunoactivity occurs in a minority of patients with lung cancer, particularly those with extensive small-cell carcinoma. Indirect evidence suggests that the high ACTH levels detected with assays for total ACTH are due to molecular forms other than 1-39 ACTH, probably high-mol.-wt species.
THERE IS NOW considerable evidence that production of ACTH and related peptides occurs commonly in lung cancer, particularly the small-cell variety, though the overt ectopic ACTH syndrome is much less prevalent (Ratcliffe & Podmore, 1980 (Ayvazian et al., 1975 : WVolfsen & Odell, 1979 . High levels were also found in up to one-third of patients with non-malignant lung disease (Gewirtz & Yalow, 1974) . In contrast, others have reported high circulating ACTH levels in only a minority of lung-cancer patients, most of whom had small-cell tumours (Gropp et al., 1980) . However, these studies differed in several potentially important ways, including patient selection, stage of disease and tumour histology, type of sample, assay specificity and reference groups.
We have therefore attempted to define more clearly the prevalence of raised circulating ACTH-like immunoactivity in lung cancer, by comparing levels in patients with lung cancer of defined histology and stage with those in an ageand sex-matched reference group with non-malignant lung disease. Two types of radioimmunoassay have been used: an assay for "total" ACTH immunoactivity in plasma or serum without prior extraction of the hormone ("unextracted" assay) and assays for ACTH, p -melanocyte -stimulating hormone (3MSH) and lipotrophic hormone (LPH) immunoactivities after hormone extraction from plasma ("extracted" assays).
METHODS
Patients studied (Table 1 Blood samples.-Ten-ml samples of venous blood were taken between 09:00 and 10:00 h into heparinized and/or plain tubes. The heparinized blood was immediately centrifuged and the plain blood was allowed to clot at room temperature. The plasma or serum was snap-frozen in dry ice, and stored at -20°C until assayed.
Assays.-Two studies were performed using different radioimmunoassays (RIA):
Study A: Unextracted double-antibody RIA for "total" ACTH immunoactivity.-Ninetythree sera and 44 plasma samples from 113 patients with lung cancer were assayed. Both serum and plasma samples were assayed in 24 of these patients. In addition, assays were performed on serum and plasma samples from each of 30 patients with nonmalignant lung disease. This assay used human 1-39 ACTH for iodination and standardization (MRC 74/555) and an antiserum raised in rabbits against human 1-39 ACTH (kindly supplied by Dr L.
Husager, Medi-Lab, Denmark) . When compared to human 1-39 ACTH, this antiserum cross-reacted 98% with 1-24 ACTH, but showed no significant cross-reaction with human 18-39 ACTH, human f and yLPH, human flMSH, ,B-endorphin and leu-and met-enkephalins. The ACTH assay was performed as follows: 200 ,ul serum, plasma or standard solution was incubated overnight at 4°C with 200 pl saline/albumin diluent, 100 ,A antiserum (final dilution 1:48,000 in EDTA containing phosphate buffer) and 100 ,Iu 1251-ACTH ( 25 pg).
Carrier normal rabbit serum and donkey anti-rabbit serum (100 ,ul each) were added and incubated overnight at 4°C. After Ratcliffe & Edwards (1971) . This method selects against high-mol-wt ACTH components and C-terminal ACTH fragments so that the extracted ACTH assay is relatively specific for 1-39 ACTH. The ACTH RIA was as described by Rees et al. (1971) 
ACTIH values in plasma compared to serum
In order to determine whether ACTH levels differ in plasma and serum, both plasma and serum samples were taken at the same time from 30 control patients and the values compared. For plasma samples, the median value was between 20 and 30 ng/l and the absolute range was < 20-73 ng/l. For serum samples, the Table II summarizes the prevalence of high total ACTH levels in plasma or serum expressed in relation to the appropriate plasma or serum reference range. The patterns are similar for plasma and serum, though the smaller number of plasma samples probably makes those figures less reliable for the small cell group. Serum ACTH levels were significantly higher in patients with either limited or extensive small-cell cancer than in controls or non-small-cell cancer. Likewise the prevalence of high serum ACTH levels is much greater in patients with small-cell than non-small-cell cancer (24% vs 30o). Only 1 patient with nonsmall-cell cancer had a high serum ACTH level (55 ng/l). In the small-cell group, high serum levels were related to stage of disease, being -25-fold more frequent in patients with extensive disease. However, even in patients with high ACTH levels and small-cell cancer the degree of abnormality was modest. Six patients had levels > 100 ng/l, and only 1 had a level > 200 ng/l (250 ng/l). Table III summarizes the prevalence of elevated ACTH, fMSH and LPH levels in extracted plasma. In contrast to Study A, the levels are uniformly within the reference range, except for a single patient with non-small-cell cancer with a marginally high LPH (356 ng/l). Although the number of patients is small, particularly those with small-cell carcinoma, these data confirm the low prevalence of high levels of ACTH and related peptides in lung cancer, and suggest that the prevalence with the extracted ACTH assay is much less than with the unlextracted assay.
DISCUSSION
Our observations suggest that the prevalence of high levels of ACTH immunoactivity in patients with lung cancer is relatively low, is mainly associated with extensive small-cell cancer, and is apparently related to the specificity of the ACTH assay. The prevalence is similar to that reported by Gropp et al. (1980) , Hansen et al. (1980a) and Torstensson et al. (1980) but much lower than described by Ayvazian et al. (1975 and Wolfsen & Odell (1979) (Table IV) . We have attempted to analyse some of the factors which mav account for these discrepancies.
Type and time of sampling
Comparison of unextracted ACTH levels in plasma and serum samples (Table II) shows that levels are lower in serum than levels of ACTH, /3MSH and LPH using n methods 1\ISH (ng/l) plasma, possibly due to loss of immunoactivity during clotting, since it is well recognized that endogenous ACTH and exogenous human 1-39 ACTH are unstable in whole blood . However, comparison of plasma or serum levels in lung-cancer patients with their counterparts in control patients gave similar prevalence figures, suggesting that differences in sample handling cannot account for large variations in prevalence.
Our samples were taken in the morning, when higher ACTH levels may be expected. Others have reported a high or low prevalence irrespective of time of sampling (Table IV) .
Definition of reference range
Most previous studies have compared values in lung-cancer patients with those in normal subjects (either as absolute reference ranges or 95%I confidence limits).
We consider that age-and sex-matched patients with non-malignant lung disease and comparable smoking histories form a more appropriate reference group, since lung cancer often occurs on a background of other lung pathology. Immunoactive ACTH has been described in bronchial epithelium of a smoking dog with atypical premalignant changes (Gewirtz & Yalow, 1974) . Such changes are described in heavy smokers who died of other disease as well in the lungs of lung-cancer patients (Auerbach et al., 1961) . It is thus possible that circulating ACTH may be increased by concomitant epithelial changes as well as by tumour secretion. In addition, neuroendocrine activation in disease-induced stress may enhance pituitary ACTHB secretion. In support of this, Torstensson et al. (1980) found higher ACTH levels in patients with non-malignant lung disease than in normal subjects.
However, the selection of control patients cannot explain the different prevalences, since higher or lower figures are reported when normal subjects are used as controls. Although the low prevalence reported by Torstensson et al. (1980) may be in part related to the high control reference range, our reference range was similar to what we have found in healthy subjects. It is noteworthy that the highest prevalence figures were in studies that also reported much higher reference values than the present study. This implies differences in assay standardization and specificity (vide infra).
Nature and extent of tumour The ectopic ACTH syndrome is most commonly due to small-cell carcinoma of lung (Broder, 1979) . Other histological types of lung cancer rarely cause the syndrome. The present Study A, and that of Gropp et al. (1980) , find a greater prevalence of raised ACTH levels in small-cell carcinoma, whereas report a high prevalence in non-small-cell cancer. The latter is difficult to reconcile with a tumour origin of ACTH, since tumour-tissue concentrations are usually very low or negative for ACTH and related peptides in this histological type. It therefore seems unlikely that differences in tumour histology can account for the variation in prevalence. Similarly, differences in degree of tumour spread does not readily account for the discrepancies. Yalow et al. (1979) studied surgical cases with presumably Stage I and II tumou-s, and Wolfsen & Odell (1979) investigated patients with peripheral coin lesions and other localized radiographic abnormalities. In contrast, our series contained patients with extensive disease in whom circulating ACTH levels might be expected to be higher.
Assay specificity
A major problem in comparing previous reports is evaluation of assay specificity. Tumour and plasma ACTH from patients with ectopic ACTH syndrome, is heterogeneous, with a high but variable proportion of high-mol.-wt species and fragments (Ratter et al., 1980; Pullan et al., 1980) . Assay specificity with respect to these components is uniformly poorly defined, since purified materials are not available for formal cross-reaction studies. Most authors have employed assays which detect the N-terminal portion of ACTH and some, including our unextracted assay cross-react to an unknown extent with high-mol.-wt species.
Extraction by porous glass increases the specificity towards 1-39 ACTH and our finding of a reduced prevalence with the extracted assay confirms the report of Gewirtz & Yalow (1974) that highmol.-wt ACTH is a major component of ACTH-producing lung tumours. The low prevalence reported with a radioreceptor assay which measures predominantly 1-39 ACTH (Wolfsen & Odell 1979 ) also supports this contention. Against this, these authors also reported a high prevalence using their extracted ACTH assay which might be expected to select against high-mol.-wt forms of ACTH. Clearly, further work is required using assays of defined specificities to all the ACTH-like components in lung-cancer plasma, as assay specificity seems likely to be a major factor in accounting for these discrepancies.
In conclusion, our results show that high serum ACTH immunoactivity occurs in less than 20% of patients with lung cancer, but is commoner in extensive small-cell cancer. ACTH assays thus appear to have no value in screening or diagnosis of lung cancer. However, in patients with high ACTH levels, serial measurements could be useful in assessing response to treatment and in detecting recurrence (Hansen et al., 1980b) . Further studies should devote attention to the type of sample, selection of reference group, tumour histology and spread. However, we consider that definition of the nature of circulating ACTH in lung cancer, with development of assays specific for the tumour-related components, is a vital precondition for definitive evaluation of ACTH levels in lung cancer.
